Treatment of rats and mice with PPARα and PPARγ agonists has been shown to markedly improve the histological picture of livers in NASH animals, with concurrently increased mRNA and protein expression of adiponectin receptors 1 and 2 in liver and visceral fat [28,29,30,31]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.